These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32530728)

  • 21. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China.
    Zhao D; Gai Tobe R; Cui M; He J; Wu B
    Vaccine; 2016 Dec; 34(50):6158-6165. PubMed ID: 27838068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumococcal polysaccharide vaccination among adults aged 65 years and older, U.S., 1989-2008.
    Lu PJ; Nuorti JP
    Am J Prev Med; 2010 Oct; 39(4):287-95. PubMed ID: 20837278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in childhood pneumococcal vaccine coverage in Shanghai, China, 2005-2011: a retrospective cohort study.
    Boulton ML; Ravi NS; Sun X; Huang Z; Wagner AL
    BMC Public Health; 2016 Feb; 16():109. PubMed ID: 26830912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
    Kang DW; Kim CR; Song JY; Park SK
    Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: Does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil.
    Rezende RPV; Oliveira-Santos M; Andrade LEC; Klumb EM
    Lupus; 2023 Apr; 32(5):694-703. PubMed ID: 36705619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician's attitude.
    Nakamura A; Kawakami K; Wakana A; Folaranmi TA; Iino T
    Hum Vaccin Immunother; 2020 Sep; 16(9):2292-2299. PubMed ID: 32045317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Safety evaluation of mass inoculation of 23 valent pneumococcal polysaccharide vaccine among elderly people aged 60 and above in Shanghai from 2013 to 2017].
    Guo X; Qiu J; Ren J; Liu JC; Sun XD
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):929-933. PubMed ID: 32907280
    [No Abstract]   [Full Text] [Related]  

  • 29. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
    ;
    MMWR Morb Mortal Wkly Rep; 2010 Sep; 59(34):1102-6. PubMed ID: 20814406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014.
    Liu Y; Wang J; Liu S; Du J; Wang L; Gu W; Xu Y; Zuo S; Xu E; An Z
    Vaccine; 2017 Mar; 35(9):1281-1286. PubMed ID: 28161421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence.
    Niederman MS; Folaranmi T; Buchwald UK; Musey L; Cripps AW; Johnson KD
    Expert Rev Vaccines; 2021 Mar; 20(3):243-256. PubMed ID: 33478306
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
    Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
    Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009.
    Lu PJ; Nuorti JP
    Am J Epidemiol; 2012 Apr; 175(8):827-37. PubMed ID: 22403807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults.
    Shiramoto M; Hanada R; Juergens C; Shoji Y; Yoshida M; Ballan B; Cooper D; Gruber WC; Scott DA; Schmoele-Thoma B
    Hum Vaccin Immunother; 2015; 11(9):2198-206. PubMed ID: 26176163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older.
    Buchwald UK; Andrews CP; Ervin J; Peterson JT; Tamms GM; Krupa D; Ajiboye P; Roalfe L; Krick AL; Sterling TM; Wang M; Martin JC; Stek JE; Kohn MA; Folaranmi T; Abeygunawardana C; Hartzel J; Musey LK;
    Hum Vaccin Immunother; 2021 Aug; 17(8):2678-2690. PubMed ID: 34019468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular, Neurological, and Immunological Adverse Events and the 23-Valent Pneumococcal Polysaccharide Vaccine.
    Yoon D; Jeon HL; Kim JH; Lee H; Shin JY
    JAMA Netw Open; 2024 Jan; 7(1):e2352597. PubMed ID: 38252436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
    Ahn JG; Kim HW; Choi HJ; Lee JH; Kim KH
    Vaccine; 2015 Sep; 33(38):4770-5. PubMed ID: 26277073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year.
    Pierre É; Pladys A; Bayat-Makoei S; Tattevin P; Vigneau C
    Vaccine; 2023 Jun; 41(24):3655-3662. PubMed ID: 37179164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.